Sarah Cannon Research UK specialises in the development of novel cancer therapies by providing clinical research and personalised medicine options for cancer patients throughout the United Kingdom. As the first unit outside the NHS to offer new anti-cancer drugs in clinical trials, Sarah Cannon Research UK provides rapid access to investigational drug therapies open to both private and NHS patients. Sarah Cannon Research UK works with six central London hospitals and an expert group of 60 oncologists through HCA, Sarah Cannon’s parent organization.

For more information about how we are fighting cancer together in the UK, visit

Sarah Cannon Research UK